Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Molecular Partners AG ADR (MOLN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/13/2025: MOLN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10.83
1 Year Target Price $10.83
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 45.23% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 160.07M USD | Price to earnings Ratio - | 1Y Target Price 10.83 |
Price to earnings Ratio - | 1Y Target Price 10.83 | ||
Volume (30-day avg) 4 | Beta 0.56 | 52 Weeks Range 3.36 - 6.14 | Updated Date 11/14/2025 |
52 Weeks Range 3.36 - 6.14 | Updated Date 11/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.03 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-30 | When - | Estimate -0.4795 | Actual -0.33 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -27.01% | Return on Equity (TTM) -51.42% |
Valuation
Trailing PE - | Forward PE 1.78 | Enterprise Value 36734931 | Price to Sales(TTM) 199.56 |
Enterprise Value 36734931 | Price to Sales(TTM) 199.56 | ||
Enterprise Value to Revenue 3.81 | Enterprise Value to EBITDA 1.23 | Shares Outstanding 37399152 | Shares Floating 17489339 |
Shares Outstanding 37399152 | Shares Floating 17489339 | ||
Percent Insiders - | Percent Institutions 9.59 |
Upturn AI SWOT
Molecular Partners AG ADR
Company Overview
History and Background
Molecular Partners AG was founded in 2004, focusing on developing DARPin therapeutics, a class of protein therapeutics with unique binding properties. It has evolved from a research-focused company to one with clinical-stage programs and partnerships.
Core Business Areas
- DARPin Therapeutics: Development and commercialization of DARPin-based therapies targeting various diseases, including oncology and ophthalmology.
- Partnerships and Licensing: Collaborating with pharmaceutical companies to develop and commercialize DARPin therapeutics for specific indications.
Leadership and Structure
The company is led by its CEO and executive management team, with a board of directors providing oversight. Organizational structure involves research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- Ensovibep (MP0420): A DARPin therapeutic developed in collaboration with Novartis for the treatment of COVID-19. Clinical data has shown efficacy in reducing hospitalization and death. Market share data is difficult to ascertain. Competitors include Pfizer (Paxlovid), Merck (Molnupiravir), and Regeneron (monoclonal antibodies, though limited use now).
- MP0310: A FAP-targeting DARPin therapeutic in clinical development for oncology indications. Currently no market share as its not approved. Competitors: Other companies developing FAP-targeting therapies.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and research-intensive, with a growing focus on biologics and targeted therapies. DARPin technology offers a novel approach with potential advantages over traditional antibodies.
Positioning
Molecular Partners AG is positioned as an innovator in the field of protein therapeutics, with a focus on DARPin technology. Its competitive advantage lies in the unique properties of DARPins, such as high binding affinity and modularity.
Total Addressable Market (TAM)
The total addressable market varies greatly depending on the specific indications targeted. For example, the COVID-19 therapeutics market was significant during the pandemic. The oncology market is also substantial. Molecular Partners AG's TAM depends on the success of its pipeline and partnerships.
Upturn SWOT Analysis
Strengths
- Novel DARPin technology platform
- Strong intellectual property position
- Strategic partnerships with major pharmaceutical companies
- Promising clinical data for lead candidates
Weaknesses
- Limited commercial infrastructure
- Reliance on partnerships for commercialization
- High research and development costs
- Need for FDA approval
Opportunities
- Expansion of DARPin technology to new therapeutic areas
- Potential for strategic acquisitions or licensing deals
- Increasing demand for targeted therapies
- Regulatory pathways for accelerated approval
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- PFE
- MRK
- REGN
Competitive Landscape
Molecular Partners AG competes with established pharmaceutical companies in the biologics and targeted therapy market. It aims to differentiate itself through its DARPin technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is driven by successful clinical trials and partnerships.
Future Projections: Future growth depends on the success of its clinical pipeline and the ability to secure further partnerships. Analyst estimates are not readily available.
Recent Initiatives: Recent initiatives include advancing clinical trials for lead candidates, and seeking new partnerships.
Summary
Molecular Partners AG is a clinical-stage biotech firm leveraging its unique DARPin technology. While they have secured partnerships, they also face risks associated with clinical trial outcomes, regulatory hurdles, and competition. Success hinges on the progress of their drug pipeline and strategic partnerships. The company has been halted due to a delisting, presenting uncertainty.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- Press Releases
- SEC Filings
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Molecular Partners AG ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-06-16 | Co-Founder, CEO, Member of Management Board & Director Dr. Patrick Amstutz Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 158 | |
Full time employees 158 | |||
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease. In addition, the company develops MP0621, a molecular partners' first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.